Cargando…
Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients
Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, might predict resistance to endocrine therapy (ET) in patient...
Autores principales: | Paoletti, Costanza, Regan, Meredith M., Niman, Samuel M., Dolce, Emily M., Darga, Elizabeth P., Liu, Minetta C., Marcom, P. Kelly, Hart, Lowell L., Smith, John W., Tedesco, Karen L., Amir, Eitan, Krop, Ian E., DeMichele, Angela M., Goodwin, Pamela J., Block, Margaret, Aung, Kimberly, Brown, Martha E., McCormack, Robert T., Hayes, Daniel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196036/ https://www.ncbi.nlm.nih.gov/pubmed/34117261 http://dx.doi.org/10.1038/s41523-021-00281-1 |
Ejemplares similares
-
Improved adjuvant endocrine therapy for premenopausal women with endocrine responsive disease
por: Goldhirsch, Aron, et al.
Publicado: (2015) -
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017) -
Response to Letter to the Editor: “Endocrine Disorders in Primary Mitochondrial Disease”
por: Al-Gadi, Iman, et al.
Publicado: (2018) -
Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection
por: Cani, Andi K., et al.
Publicado: (2021) -
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
por: Darga, Elizabeth P., et al.
Publicado: (2021)